LEXINGTON, Mass., May 10 /PRNewswire-FirstCall/ -- MacroChem Corporation , a specialty pharmaceutical company, has announced that Robert J. DeLuccia, its president and chief executive officer, will present an update on the Company’s technologies, products and business strategy at the Rodman & Renshaw 3rd Annual Global Healthcare Conference. MacroChem, which began trading under its new symbol on February 10, 2006, recently raised $8.25 mil in a private placement to focus on advancing its lead product candidate, EcoNailTM, for the treatment of onychomycosis (nail fungus).
The Company is in the process of manufacturing clinical supplies and submitting the proposed EcoNail Phase 2 protocol for IRB (Institutional Review Board) review. The proposed protocol calls for a 48-week treatment duration and efficacy assessments using standard criteria of nail appearance and mycology. The Company expects the Phase 2 trial to commence later this quarter and the proposed protocol anticipates an interim assessment after all patients complete 24 weeks of treatment. At both the interim and final assessments, the Company plans to utilize a panel of independent onychomycosis experts to assist with the efficacy evaluations.
The Conference will take place at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco, on May 15-16, 2006. Mr. DeLuccia’s presentation will be on Tuesday, May 16, at 12:40 pm (Europe) CEST time, in the Atlantique Salon -- Meridional (2nd Floor) and he will be available to meet one-on-one with investors during the conference.
Mr. DeLuccia’s presentation will be accessible live via webcast and for replay at http://www.wsw.com/webcast/rrshq8/mchm/.
Rodman and Renshaw is a full service investment bank. For more information about Rodman & Renshaw conferences, visit http://www.rodmanandrenshaw.com/conferences.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA(R): EcoNail, to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin. For more information visit our website, http://www.macrochem.com.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem’s actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled “Risk Factors” in MacroChem’s Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.
Investor/Media Contact: Bernard Patriacca - VP/CFO
(781) 862-4003
MacroChem Corporation
CONTACT: Bernard Patriacca, VP/CFO of MacroChem, +1-781-862-4003
Web site: http://www.macrochem.com//
